未來世界(00572.HK)飆升69%曾逼近七個月高 獲COVID-19檢測盒本港獨家分銷權
未來世界控股(00572.HK)獲COVID-19檢測盒本港獨家分銷權。該股今早幅飆升89%至0.375元,創近七個月高,受制牛熊線(0.378元),現造0.335元,飆升69%,一向稀疏成交急增至6,202萬股。
未來世界公布,全資附屬天信國際已按獨家基準獲授權及委任為溫州甌佳生物科技(OJABIO)之香港獨家授權分銷商,包括COVID-19抗原檢測盒及COVID-19即時聚合(酉每)連鎖反應檢測盒,為期三年。該檢測盒已取得相關認證,可為社會提供可負擔「早期診斷」解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.